本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 董事長兼執行董事 王威東先生 中國煙台 2026年1月21日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 | 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2026-005 | | --- | --- | --- | | 港股代码：09995 | 港股简称 ...

本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 767,240股。 本次股票上市流通总数为767,240股。 本次股票上市流通日期为2026 年 1 月 26 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，荣昌生物制药（烟台）股份有限公司（以下简 称"公司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变 更登记证明》，公司完成了 2022 年 A 股限制性股票激励计划 A 类权益第三个归 属期及 B 类权益首次授予第二个归属期、2023 年 A 股限制性股票激励计划首次授 予第一个归属期限制性股票的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 | 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2026-005 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 2022年及 2023年 A股限制性股票激励计划相关权益对 应归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公 ...

创业板指冲高回落涨0.54%、科创50涨超3.5%，半导体产业链全线爆发。锋龙股份16连板，广电电气4连板，一图看懂>> 红 宝 丽 2天2板 公司主要从事环氧丙烷衍生品,一异丙醇胺可用于电子化学品之光刻胶清洗剂,也是近 年来公司在国内市场重点拓展的应用领域之一 AIET AI4S推动创新药发展;荣昌生物与艾伯维达成超50亿美元BD 澳佳华 旗下AI按摩机器人运用了语音交互、人脸识别、智能生理参数检测等技术，还接入 DeepSeek,打造健康生态AI大模型 液晶面板/LCD 三利谱 国内偏光片行业龙头企业之一,国内少数具备TFT-LCD用偏光片生产能力的企业之一, 是华为等全球著名终端品牌显示屏材料供应商 深纺织A 深圳国资委控股的纺织集团旗下,主营液晶显示用偏光片 人工智能大模型 DeepSeek或2月发布新一代旗舰模型,具备强大编程能力 环球印务 子公司领凯科技逐步引入ChatGPT技术,在数字化广告营销中为广告智能投放、素材自 动化创作、直播带货业务场景及智能对话客服等方面赋能 房地产 住建部部长:今年将着力稳定房地产市场,支持房企合理的融资需求 德才股份 6天3板 山东省唯一建筑装饰上市企业,主业覆盖 ...

Group 1 - The core viewpoint of the news highlights the growth of the biomedical sector in China's STAR Market, with the STAR Market Biomedical Index rising by 0.29% and specific stocks like Tianzhihang increasing by 14.64% [1] - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary medical services, establishing a fee framework for innovative technologies such as surgical robots and remote surgeries, promoting a coefficient-based charging model linked to robotic assistance [1] - Guohai Securities points out that artificial intelligence is accelerating the empowerment of the entire pharmaceutical industry chain, with NVIDIA and Eli Lilly announcing a joint AI innovation lab, investing up to $1 billion over five years to explore AI applications in drug discovery, development, and manufacturing [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the STAR Market Biomedical Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [1] - The STAR Market Medical ETF by Harvest (588700) closely tracks the STAR Market Biomedical Index, providing an easy investment opportunity in the biomedical sector for investors without stock accounts through the Harvest Medical ETF linked fund (021061) [2]

Core Insights - The report highlights the significant fluctuations in the Japanese bond market, with calls from the Japanese Finance Minister for investors to remain calm amid a sell-off that has affected U.S. bonds as well [8][12] - China has introduced a series of policy measures aimed at boosting investment and consumption, including a special guarantee plan worth 500 billion RMB (approximately 72 billion USD) to encourage private enterprises to borrow and expand their businesses [8][12] Market Performance - The Shanghai Composite Index closed at 4113.65 points, down 0.01%, while the Shenzhen Component fell by 0.97% and the ChiNext Index dropped by 1.79% [1][5] - The Hang Seng Index ended at 26487.51 points, down 0.29%, with the Hang Seng Technology Index declining by 1.16% and the Hang Seng China Enterprises Index falling by 0.43% [1][5] - U.S. markets also experienced declines, with the Dow Jones Industrial Average down 1.76% at 48488.59 points, the S&P 500 down 2.06% at 6796.86 points, and the Nasdaq down 2.39% [1][5] Company Developments - China’s leading PCB equipment manufacturer, Dazhu CNC, reported a 144% year-on-year increase in net profit for the first ten months of the previous year, with revenues rising by 64.4% [10] - Junlebao Dairy, a comprehensive dairy company in China, submitted its listing application to the Hong Kong Stock Exchange, reporting a nearly 30% increase in net profit for the first nine months of the previous year [10] - Muyuan Foods, a major pig farming and pork production company in China, is reportedly planning to raise up to 11.7 billion HKD (approximately 1.5 billion USD) through a Hong Kong IPO [10] - Shanghai Shangmi Technology is expected to launch an IPO in February, aiming to raise around 12 billion HKD (approximately 1.5 billion USD) [10] Economic Indicators - China's GDP growth for the fourth quarter was reported at 4.5%, with a year-to-date growth of 5.0% [16] - The retail sales of consumer goods in China for December showed a year-on-year increase of 0.9%, while industrial value-added output rose by 5.2% [16]

Group 1 - The Hong Kong Innovation Drug ETF (159570) has seen a significant inflow of funds, with a recent trading volume exceeding 5 billion yuan and a net inflow of over 300 million yuan in the past five days [1] - As of January 20, the total size of the Hong Kong Innovation Drug ETF reached over 25.3 billion yuan, leading the market in terms of scale among innovation drug ETFs [1] - The index components of the ETF showed mixed performance, with notable gains from companies like Kingsoft Biotech and China Biologic Products, while companies like CanSino Biologics experienced declines [3][4] Group 2 - At the J.P. Morgan Healthcare Conference, several Chinese pharmaceutical companies showcased their advancements, including BeiGene's new drug approval in China and plans for accelerated approval in the U.S. [5] - Innovent Biologics and Pfizer are set to conduct five global Phase III trials for their drug SSGJ-707 by 2026, targeting various cancers [6] - The collaboration between NVIDIA and Eli Lilly aims to establish an AI innovation lab with a projected investment of up to 1 billion USD over five years, potentially transforming drug development processes [8] Group 3 - Tempus AI reported a revenue of approximately 1.27 billion USD for 2025, marking an 83% year-on-year increase, driven by significant growth in its diagnostic business [9] - The top ten components of the Hong Kong Innovation Drug ETF account for over 73% of its weight, highlighting the concentration of leading innovative drug companies within the ETF [10]

截至2026年1月20日，本公司已透过上海证券交易所的交易系统以集中竞价交易方式累计回购19.41万股 本公司股份，占本公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为 每股人民币102.17 元，所付资金总额为人民币2000.4万元（不包括交易费用）。本公司的股份回购已达 回购资金总额的下限，且并无超越回购资金总额的上限，回购计划已完全实施。 责任编辑：卢昱君 热点栏目自选股 数据中心 行情中心 资金流向 模拟交易客户端 荣昌生物（09995）发布公告，于2026年1月20日，本公司透过上海证券交易所的交易系统以集中竞价交 易方式首次回购19.41万股本公司股份，占本公司股本总数5.64亿股的 0.0344%。回购交易的最高价格为 每股人民币103.78元、最低价格为每股人民币102.17元，所付资金总额为人民币2000.4万元（不包括交 易费用）。 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [31]. Core Insights - The JPMorgan Healthcare Conference highlighted six top candidate drugs in the Chinese market for 2026, with four originating from local innovative companies, showcasing their R&D capabilities that can compete with multinational brands [4]. - The report anticipates continued active merger and acquisition (M&A) transactions in the biopharmaceutical sector, with a projected global M&A transaction volume reaching $5.1 trillion in 2025, led by a 44% increase in the healthcare sector [4]. - Investment strategies suggest focusing on innovative Chinese pharmaceutical companies that are enhancing their global competitiveness, particularly in therapeutic areas like metabolism, chronic diseases, and central nervous system disorders, as well as potential technology platforms such as small nucleic acid drugs and CAR-T therapies [5]. Summary by Sections Industry Overview - The JPMorgan Healthcare Conference showcased 24 Chinese innovative pharmaceutical companies, including BeiGene and Legend Biotech, presenting their latest R&D and commercialization achievements [4]. - The report emphasizes the importance of the Chinese market, identifying six candidate drugs that are expected to make significant impacts in 2026 [4]. Investment Strategy - The report recommends focusing on innovative therapeutic areas beyond traditional oncology and immunology, such as metabolic disorders and chronic diseases [5]. - It also highlights the potential of emerging technology platforms, suggesting investment in companies that are advancing in areas like peptide drugs and small nucleic acids [5]. Market Performance - The pharmaceutical sector experienced a decline of 0.68% last week, while the Shanghai and Shenzhen 300 Index fell by 0.57%, ranking the pharmaceutical industry 17th among 27 sectors [20]. - In contrast, the Hong Kong pharmaceutical sector saw an increase of 2.38%, outperforming the Hang Seng Index, which rose by 2.56%, ranking 6th among 11 sectors [30].

格隆汇1月21日丨荣昌生物(09995.HK)发布公告，2026年1月20日耗资人民币2000.4万元回购19.41万股A 股，回购价格每股102.17-103.78元。 截至2026年1月20日，公司已透过上交所的交易系统以集中竞价交易方式累计回购19.41万股公司股份， 占公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为每股人民币 102.17元，所付资金总额为人民币2000.4万元(不包括交易费用)。公司的股份回购已达回购资金总额的 下限，且并无超越回购资金总额的上限，回购计划已完全实施。 ...

截至2026年1月20日，本公司已透过上海证券交易所的交易系统以集中竞价交易方式累计回购19.41万股 本公司股份，占本公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为 每股人民币102.17元，所付资金总额为人民币2000.4万元(不包括交易费用)。本公司的股份回购已达回 购资金总额的下限，且并无超越回购资金总额的上限，回购计划已完全实施。 荣昌生物(09995)发布公告，于2026年1月20日，本公司透过上海证券交易所的交易系统以集中竞价交易 方式首次回购19.41万股本公司股份，占本公司股本总数5.64亿股的0.0344%。回购交易的最高价格为每 股人民币103.78元、最低价格为每股人民币102.17元，所付资金总额为人民币2000.4万元(不包括交易费 用)。 ...